Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report
(2021) Frontiers in Oncology — Vol. 11 (2021)
Files
fonc-11-764758.pdf
Open Access - Adobe PDF
- 3.84 MB
Details
- Authors
- Abstract
- Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or stereotactic body radiotherapy is currently evaluated. Visceral metastases are less common and have very poor prognosis in mPC. Whether treating isolated visceral metastases such as liver metastases with MDT could increase the prognosis remains unknown. We report the management of a prostate cancer patient who progressed on androgen deprivation therapy with apparition of two liver metastases. We describe the feasibility of combining MDT with abiraterone acetate and prednisone in a patient with metastatic castration-resistant prostate cancer. MDT allowed the interruption of abiraterone acetate, preventing cumulative toxicity of this agent.
- Affiliations
Jolimont Hospital, La Louvière, Belgium Department of Medical Oncology Jolimont Hospital, La Louvière, Belgium Department of Radiotherapy Jolimont Hospital, La Louvière, Belgium Department of Surgery Jolimont Hospital, La Louvière, Belgium Department of Pathology
Citations
Yeo, A.-E., Hendrix, A., Confente, C., Christian, N., Mansvelt, B., Pairet, G., & Seront, E. (2021). Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.764758 (Original work published 2021)